Elanco Animal Health Incorporated Common Stock (ELAN)
10.80
-0.51 (-4.51%)
Elanco Animal Health Inc is a global leader in the development and manufacturing of products for animal health and well-being
The company focuses on providing innovative solutions for companion and livestock animals, which include a wide range of vaccines, pharmaceuticals, and nutritional products designed to prevent and treat diseases. By combining science and technology, Elanco aims to enhance animal care and improve food safety while promoting sustainable farming practices. With a commitment to animal health and welfare, the company partners with veterinarians, farmers, and pet owners to deliver effective health management solutions.
Animal health company Elanco (NYSEELAN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales fell by 1.4% year on year to $1.02 billion. On the other hand, the company’s full-year revenue guidance of $4.48 billion at the midpoint came in 1.2% below analysts’ estimates. Its non-GAAP profit of $0.14 per share was in line with analysts’ consensus estimates.
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.
Elanco Animal Health reports Q3 revenue of $1.03 billion, with a 4% decline and adjusted EPS of $0.13, beating estimates. Guidance tightened for 2024 sales and EPS.
FDA approves Elanco's once-daily oral treatment, Zenrelia, for controlling itching in dogs with allergic and atopic dermatitis. The drug, proven effective in studies, faces adoption challenges due to vaccination warnings and adverse event concerns.
Merck Animal Health announced the purchase of Elanco Animal Health's aquaculture business.Merck & Company (NYSEMRK) completed the acquisition of the aquaculture bus
Elanco Animal Health shares drop after updates on FDA approval timelines for Zenrelia and Credelio Quattro. Zenrelia's U.S. label includes a boxed warning, impacting adoption. U.S. launches for both drugs are planned for late 2024 and early 2025.
